08 January 2018 | News
Perrigo announces tentative FDA approval for a first-to-file generic version of Prolensa Ophthalmic Solution 0.07%
Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products.
The company has received tentative approval from the U.S. Food and Drug Administration for the generic version of Prolensa® (bromfenac ophthalmic solution) 0.07%.
Perrigo previously settled litigation with Bausch & Lomb Inc. for this product.
Prolensa® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID).
It is specified for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Branded market sales for the last twelve months were approximately $113 million.